Optinose Us Inc patents expiration
1. Xhance patents expiration
XHANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8327844 | OPTINOSE US INC | Nasal delivery method |
Oct, 2023
(20 days from now) | |
| US8522778 | OPTINOSE US INC | Nasal devices |
Apr, 2024
(6 months from now) | |
| US7975690 | OPTINOSE US INC | Nasal devices |
Dec, 2025
(2 years from now) | |
| US10124132 | OPTINOSE US INC | Nasal delivery |
Mar, 2027
(3 years from now) | |
| US11602603 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2028
(5 years from now) | |
| US10076615 | OPTINOSE US INC | Nasal delivery |
Jul, 2029
(5 years from now) | |
| US8550073 | OPTINOSE US INC | Nasal delivery |
Oct, 2029
(6 years from now) | |
| US8978647 | OPTINOSE US INC | Nasal delivery |
Dec, 2030
(7 years from now) | |
| US10252010 | OPTINOSE US INC | Nasal delivery devices |
Feb, 2031
(7 years from now) | |
| US11033696 | OPTINOSE US INC | Nasal delivery devices |
May, 2033
(9 years from now) | |
| US10179216 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2033
(9 years from now) | |
| US10478574 | OPTINOSE US INC | Nasal administration |
Nov, 2033
(10 years from now) | |
| US10076614 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2034
(11 years from now) | |
| US10300229 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2035
(11 years from now) | |
| US11554229 | OPTINOSE US INC | Nasal administration |
Feb, 2036
(12 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
XHANCE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic